Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BI 655066 versus placebo in moderate to severe Crohn's disease
NL-OMON41584Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of risankizumab in Crohn's disease (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Clinical remission at 12 weeks. Started Apr 2015; status: active, not recruiting.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON41584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41584.